Indoco Remedies Standalone March 2020 Net Sales at Rs 272.02 crore, up 7.94% Y-o-Y
NULL24-06-2020
INDOCO REMEDIES LTD. - 532612 - Corporate Action-Board to consider Dividend
Dividend for the year 2019-202024-06-2020
INDOCO REMEDIES LTD. - 532612 - Board recommends Dividend
Indoco Remedies Ltd has informed BSE that the Board of Directors of the Company at its meeting held on June 24, 2020, inter alia, has recommended dividend of Rs.0.30/ - per share (15%) on face value of Rs. 2/- each for the financial year 2019-2020,subject to the Members approval at the AGM.24-06-2020
INDOCO REMEDIES LTD. - 532612 - Results - Financial Results For Year Ended 31.03.2020
Financial Results for the quarter & year ended 31.03.202024-06-2020
INDOCO REMEDIES LTD. - 532612 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayINDOCO REMEDIES LTD. 2CINL85190MH1947PLC005913 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 92.11 4Highest Credit Rating during the previous FY A 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)ICRA LIMITED 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkNSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: JAYSHANKAR MENON Designation: COMPANY SECRETARY EmailId: [email protected] Name of the Chief Financial Officer: MANDAR BORKAR Designation: CHIEF FINANCIAL OFFICER EmailId: [email protected] Date: 10/06/2020 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.10-06-2020
INDOCO REMEDIES LTD. - 532612 - Announcement Under Reg 30Of SEBI (LODR) Reg 2015 - Concall Meeting
Schedule of concall meeting04-06-2020
INDOCO REMEDIES LTD. - 532612 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Publication of Board Meeting Notice02-06-2020
INDOCO REMEDIES LTD. - 532612 - Board Meeting Intimation for Approval Of Audited Accounts
INDOCO REMEDIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/06/2020 ,inter alia, to consider and approve Audited Financial results for the year ended 31st March 202001-06-2020
Indoco Remedies share price up nearly 5% on USFDA approval
The company received the approval for Succinylcholine Chloride Injection USP, a muscle relaxant that is also being used for some COVID-19 patients.26-05-2020